

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

IL3RA RABBIT PAB

货号: \$219865 产品全名: IL3RA 兔多抗

基因符号 IL3R; CD123; IL3RX; IL3RY; IL3RAY; hlL-3Ra
UNIPROT ID: P26951 (Gene Accession - NP_002174)

背景: The protein encoded by this gene is an interleukin 3 specific subunit of a heterodimeric cytokine receptor. The receptor is comprised of a ligand specific alpha subunit and a signal transducing beta subunit shared by the receptors for interleukin 3 (IL3), colony stimulating factor 2 (CSF2/GM-CSF), and interleukin 5 (IL5). The binding of this protein to IL3 depends on the beta subunit. The beta subunit is activated by the ligand binding, and is required for the biological activities of IL3. This gene and the gene encoding the colony stimulating factor 2 receptor alpha chain (CSF2RA) form a cytokine receptor gene cluster in a X-Y pseudoautosomal region on chromosomes X or Y. Alternatively spliced transcript variants encoding distinct isoforms have been found.

抗原: Synthetic peptide of human IL3RA

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219865(IL3RA Antibody) at a dilution of 1/50(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 219865(Anti-IL3RA Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffinembedded Human prostate cancer tissue using 219865(Anti-IL3RA



In comparision with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with synthetic peptide



Product Description

Pioneering GTPase and Oncogene Product Development since 2010